The Legislative Assembly of Santa Catarina (Alesc) is currently reviewing a proposed law (PL 0766/2025) that aims to offer free Tirzepatide, a medication administered via weight loss pens, to individuals classified with grade III obesity. This condition, defined by a Body Mass Index (BMI) of 40 kg/m² or higher, is perceived as critical according to World Health Organization standards. The bill, introduced in October 2025 by Deputy Sérgio Motta from the Republicans party, has gained significant attention due to the medication's popularity in Brazil for weight loss purposes.

As of now, the bill is under analysis by the Commission of Finance and Taxation. Recently, one of the legislators requested additional time to examine the proposed law further, which means there is currently no set timeline for when this legislation will be reconsidered. The demand for efficient measures addressing obesity, especially in younger populations, is becoming increasingly urgent as society grapples with the growing obesity epidemic.

The current bill aims to specifically target patients aged between 16 and 18 years who meet the criteria for severe obesity, which points to a progressive public health initiative focused on combating obesity in young adults. As discussions around this law continue, its ultimate implications for public health policy and accessibility to treatments for obesity will be critical, especially as obesity rates rise in Brazil.